Japan's Teijin To Apply For U.S.-Approved Gout Drug In Japan, Europe
This article was originally published in PharmAsia News
Executive Summary
Teijin Pharma of Japan says it is ready to seek approval in Japan and Europe to market a gout drug TMX-67 (febuxostat) that the maker expects will become a blockbuster. Teijin has had trouble getting the drug approved in Japan, where regulatory authorities required additional clinical trials, so Teijin plans to reapply this year, in time to release it locally in 2011. Takeda Pharmaceutical markets Teijin's drug in the United States as Uloric. (Click here for more - a subscription may be required